Germany's special AMNOG rules for orphan drugs are facing growing scrutiny. The Health Financing Commission (FinanzKommission Gesundheit) recommends abolishing the orphan drug privilege, while the Institute for Quality and Efficiency in Health Care (IQWiG) and other stakeholders are discussing changes to the benefit assessment of medicines for rare diseases. At the centre of the debate is a statutory provision under which an orphan drug's added benefit is initially deemed proven by virtue of its marketing authorisation.
Criticism focuses on the gap between this legally presumed added benefit and the available comparative clinical evidence. Studies of subsequent full benefit assessments indicate that an added benefit over the appropriate comparator therapy often cannot be demonstrated. This raises the question of whether incentives for orphan drug development should continue to operate through the legal determination of added benefit.
The orphan drug privilege allows added benefit to be presumed without a standard comparison against the appropriate comparator therapy
Under Germany's AMNOG framework, the medical added benefit of an orphan drug is initially deemed proven by law. Section 35a(1), sentence 11, of Book V of the German Social Code (SGB V) links this legal presumption to the medicine's marketing authorisation. In the privileged procedure, the Federal Joint Committee (G-BA) therefore assesses the extent of added benefit that can be derived from the available authorisation studies rather than first requiring proof of added benefit over an appropriate comparator therapy (zweckmäßige Vergleichstherapie, zVT).
The special rule reflects challenges in developing medicines for rare diseases. Small patient populations, heterogeneous disease courses and limited treatment options can make comparative trials difficult. Orphan designation does not, however, necessarily mean that no treatment alternatives exist. Designation may also be granted where a medicine is expected to offer significant benefit over existing methods of treatment.
Regulatory orphan status must be distinguished from the German presumption of added benefit. While the EU Pharmaceutical Reform and orphan drug exclusivity is set to reorganise market exclusivity periods, the German reform debate concerns the conditions for establishing added benefit under AMNOG.
In the privileged procedure, the G-BA may conclude that the extent of the legally presumed added benefit is non-quantifiable. This differs fundamentally from a finding that added benefit has not been proven in a standard benefit assessment. The former describes the inability to quantify the extent of an added benefit presumed by law. The latter means that the submitted evidence does not adequately demonstrate added benefit over the zVT.
The privilege is also subject to a revenue threshold. Once a medicine's sales to Germany's statutory health insurance system exceed EUR 30 million within twelve calendar months, the manufacturer must undergo a full benefit assessment and submit a complete dossier. Added benefit is then assessed against the zVT specified by the G-BA.
The evidentiary requirements for the same medicine can therefore change substantially over its lifecycle. The general course of early benefit assessment is described in our guide to the AMNOG process.
Previous orphan drug assessments reveal the limits of the statutory presumption of added benefit
Legal recognition of added benefit does not establish whether the available clinical evidence can reliably quantify its extent. This distinction is apparent in both initial orphan drug assessments and subsequent standard assessments.
An analysis of 347 G-BA decisions reported in a specialist article on orphan drugs in AMNOG illustrates how frequently the extent of added benefit could not be quantified. In 175 decisions, the extent was classified as non-quantifiable. A quantifiable added benefit was reported in 108 decisions. The remaining 64 decisions fell into other outcome categories, including cases in which added benefit was not proven or a lesser benefit was identified.
These results require careful separation by assessment type. The dataset covers different procedural settings and cannot directly establish how often a medicine initially assessed under the orphan privilege subsequently fails to demonstrate added benefit in a full assessment. It does indicate that the statutory presumption frequently coexists with insufficient evidence to quantify the extent of added benefit.
Studies of subsequent full assessments provide a different perspective. In its March 2026 report, the Health Financing Commission cites an analysis in which no added benefit over the zVT could be demonstrated for 54% of the orphan medicines examined after standard assessment. In its September 2026 position paper, IQWiG similarly argues that the initially presumed added benefit was not confirmed in approximately half of the cases reassessed later.
These figures come from different study populations than the analysis of 347 G-BA decisions. They should not be combined into a single success or failure rate.
Their interpretation also matters. A finding of 'added benefit not proven' does not mean that a medicine is ineffective or has no therapeutic value for patients. A standard benefit assessment asks whether methodologically suitable evidence demonstrates additional patient-relevant benefit against a specified comparator therapy.
For orphan drugs, the absence of direct comparative trials, small samples and inadequately adjusted indirect comparisons can complicate this assessment. Subsequent full assessments may therefore expose evidence gaps that already existed at marketing authorisation and during the initial AMNOG procedure.
These results do not, on their own, establish that the orphan drug privilege should be abolished. They explain why its legal design is being challenged: added benefit is initially presumed even when the evidence needed for a standard comparative demonstration may be unavailable.
Germany's Health Financing Commission recommends abolishing the orphan drug privilege
The Health Financing Commission proposes ending the statutory presumption of added benefit for orphan drugs and separating incentives for rare-disease medicines more clearly from clinical benefit assessment. Recommendation 40 of its first report, dated 30 March 2026, calls for orphan drugs generally to meet the same requirements for demonstrating added benefit as other medicines.
The proposal addresses the current link between regulatory orphan designation and the added-benefit determination under German social law. In the Commission's view, orphan marketing authorisation does not in itself justify assuming additional patient-relevant benefit over available treatments.
The Commission also points to variation in the feasibility of comparative evidence generation. Suitable comparator therapies exist for some rare diseases, and randomised controlled trials are not universally infeasible. It cites an analysis suggesting that such trials would, in principle, have been possible for 68% of the orphan medicines examined.
The recommendation does not propose ignoring the specific development challenges of all rare-disease treatments. For medicines addressing ultra-rare diseases, where producing informative comparative evidence is structurally difficult, special terms in reimbursement price negotiations could remain possible.
This would change the mechanism of support. Instead of recognising added benefit by statutory presumption, specific incentives could be reflected more directly in reimbursement pricing.
The Commission also estimates a financial effect. It projects potential savings of up to EUR 30 million in 2027 and up to EUR 45 million in each of 2028 and 2029. These are estimates based on assumptions about how changed benefit assessments might affect negotiated reimbursement prices, not savings already realised.
The recommendation is not enacted legislation. It nevertheless places the future of the orphan drug privilege within the debate over how innovative medicines are financed.
IQWiG and KBV question the requirement for a full reassessment after the EUR 30 million threshold
Alongside the statutory presumption, the transition to a full benefit assessment after the revenue threshold is also being reconsidered. Statements published in September 2026 by IQWiG and the National Association of Statutory Health Insurance Physicians (Kassenärztliche Bundesvereinigung, KBV) outline different ways to assess comparative evidence earlier or avoid repeat assessments that add little new information.
IQWiG proposes defining an appropriate comparator therapy for orphan drugs from the first AMNOG assessment and methodologically evaluating the available comparative evidence. This would allow the clinical added benefit relative to a relevant treatment to be examined earlier.
The institute also discusses an option under which the legal presumption of added benefit would initially remain in place. Comparative evidence would still be assessed in full and the findings reported transparently. If the revenue threshold were exceeded later, that assessment could inform subsequent decisions without necessarily requiring another full benefit assessment.
KBV focuses more directly on procedural efficiency. In its statement of 18 September 2026, it suggests waiving a revenue-triggered reassessment where the initial procedure already established added benefit over the zVT using sufficiently reliable comparative evidence.
Where suitable comparative evidence was not initially available and no relevant new data have since emerged, KBV proposes another option. The manufacturer could initiate a formal waiver of the full reassessment, with a legally defined consequence of 'added benefit not proven'.
This would not replace missing proof with a favourable assessment. Its purpose would be to avoid a full reassessment where the lack of new comparative evidence makes substantial additional insight unlikely.
|
Proposal |
Implication for orphan drug assessment |
|---|---|
|
Health Financing Commission |
Standard benefit assessment without a statutory presumption of added benefit |
|
IQWiG |
Comparative evidence assessment from the initial procedure, potentially while retaining the statutory presumption |
|
KBV |
Targeted exemptions from repeat full assessments where comparative evidence is already sufficient or remains unavailable |
Under the current approach, the EUR 30 million threshold determines when the privileged procedure ends and a full comparative assessment is required. Whether that reassessment provides meaningful additional clinical insight depends largely on the evidence generated since the first decision.
The debate therefore concerns more than the threshold's monetary value. It also concerns when reassessment is scientifically warranted and which consequences should follow when comparative evidence is missing. The wider reform agenda is addressed separately in Delta Dossier's AMNOG 2.0 insight.
Comparative evidence remains central to orphan drug development regardless of the reform outcome
The proposed reforms differ in when comparative evidence would be assessed and what legal consequences the assessment would carry. The underlying methodological question remains: what can the available data establish about patient-relevant added benefit over existing treatment options?
For clinical development, it matters whether studies supporting marketing authorisation can also provide a credible comparison against a treatment relevant to German clinical practice.
A single-arm study may provide important information on efficacy and safety, but generally cannot directly establish how a treatment performs relative to an existing therapy. Indirect comparisons can also be limited by differences in populations, endpoints and study conditions.
These issues can be particularly difficult in rare diseases. Small populations and heterogeneous disease trajectories may constrain direct comparative research. Methodologically sound non-randomised comparisons may therefore have an important role, provided relevant prognostic factors and potential confounders can be identified, measured and appropriately accounted for.
KBV stresses that considering the best available evidence does not mean that such evidence necessarily permits added benefit to be quantified. Nor does a study accepted for regulatory purposes, or an endpoint relevant to authorisation, necessarily answer the comparative question posed by German early benefit assessment.
Orphan drug programmes therefore need to consider whether and how appropriate comparative data could be generated after approval if the original studies cannot support the relevant comparison.
The EU Joint Clinical Assessment (JCA) reinforces the need to consider comparative clinical evidence early. It evaluates relative clinical effectiveness and safety against a European assessment scope. The German determination of the zVT and the national decision on added benefit remain distinct.
The debate over the orphan drug privilege consequently also concerns the point at which comparative evidence enters the AMNOG assessment and how unmet medical need should be taken into account when a reliable comparison is not feasible.
The legislative outcome remains open. Distinguishing regulatory orphan status, legally presumed added benefit and methodologically demonstrated added benefit already matters for evidence planning today.
---
Legal status: 28 October 2026. The reform recommendations and position papers described are not current law.
Sources
Section 35a SGB V, provisions governing early benefit assessment and the orphan drug special rule.
Health Financing Commission (2026), First Report, Recommendation 40.
IQWiG (18 September 2026), position paper on the AMNOG 2.0 concept discussed in the German pharmaceutical policy dialogue.
National Association of Statutory Health Insurance Physicians (KBV, 18 September 2026), position paper on AMNOG 2.0, especially pp. 4–6.
market access & health policy, issue 01/2026, specialist article on orphan drugs under AMNOG and analysis of 347 G-BA decisions.